CliffBio
small molecule

APHEXDA

MOTIXAFORTIDE ACETATE

Loss of exclusivityDecember 2041latest FDA-listed patent expiry
CompanyAYRMID PHARMA LTD

Drug detail

Brand nameAPHEXDA
Active ingredientMOTIXAFORTIDE ACETATE
StrengthEQ 62MG BASE/VIAL
Dosage formPOWDER
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2023
Marketing statusRX

Listed patents

PatentExpiresType
12257285December 2041product
12268725December 2041product

Regulatory exclusivity

CodeExpires
ODE-442September 2030
NCESeptember 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

APHEXDA patent cliff — loss of exclusivity December 2041 | CliffBio